CCS
ALXN

Crosspoint Capital Strategies’s Alexion Pharmaceuticals ALXN Stock Holding History

Crosspoint Capital Strategies’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-200
Closed -$37K – 892
2015
Q4 		$37K Buy
+200
New +$34.9K 0.01% 488

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Crosspoint Capital Strategies's ALXN Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 200 shares — an estimated $37K sold.

Crosspoint Capital Strategies first reported a position in ALXN in Q4 2015 and held it in 1 quarter. The position peaked at $37K in Q4 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 200 Alexion Pharmaceuticals shares in Q1 2016, an estimated $37K.
  • Crosspoint Capital Strategies first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Alexion Pharmaceuticals position peaked at $37K in Q4 2015.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.